AbbVie: Combo May Provide Remission for Chronic Lymphocytic Leukemia

 The fixed-duration combination met the primary endpoint of complete response rate at 56% among patients with previously untreated CLL, 70 years old or younger

- At 24 months, progression-free survival was 95% and overall survival (OS) was 98%

- The safety profile of the combination was generally consistent with known adverse events (AEs) for each agent and no new safety signals were identified

- Data to be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7501)

AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study investigating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax), an all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) during an oral presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7501). The ibrutinib and venetoclax cohort met its primary endpoint of complete response (CR) rate of 56% (95% CI 48-64) among patients without del(17p), 70 years old or younger and with 27.9 months of follow up. This rate was higher than the 37% minimum meaningful rate study assumption (P<0.0001). The CR rate was consistent across all patients in the study including high-risk CLL patient groups. Furthermore, 24-month progression free survival (PFS) and overall survival (OS) were 95% and 98%, respectively.

https://finance.yahoo.com/news/captivate-study-shows-imbruvica-ibrutinib-153000741.html